Roche’s Analyst Event at ISTH 2017
| Agenda: | |
|---|---|
| HAVEN2: Ph3 interim data of emicizumab (ACE910) prophylaxis in pediatrics with hemophilia A with inhibitors; aspects of disease management and emicizumab global development program | Gallia Levy, M.D., Ph.D., Global Development Team Leader emicizumab |
| HAVEN1: Ph3 data of emicizumab (ACE910) prophylaxis in adults with hemophilia A with inhibitors | Prof. Dr. med. Johannes Oldenburg, University Clinic Bonn, Institute of Experimental Hematology and Transfusion Medicine |
| Welcome | Daniel O’Day, CEO Roche Pharmaceuticals |
Please register to access the replay* *Privacy notice